The following is a summary of the Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript:
Financial Performance:
Haemonetics reported Q1 revenue of $336 million, an 8% growth on a reported basis and 3% organically.
Adjusted earnings per diluted share declined by 3% to $1.02.
Adjusted gross margin was 55.3%, increasing by 110 basis points.Adjusted operating income was $71 million, up by $0.8 million.
Forecasted adjusted earnings per share for FY 2025 range from $4.45 to $4.75.
Business Progress:
Launched new products and integrated recent acquisitions.
Achieved 31% reported revenue growth in the Hospital business unit.
Plan to upgrade all Nexus customers in North America to Express Plus and Persona technologies before end of FY 2025.
Launching full market release of VASCADE MVP XL and planning to enter additional European markets this year.
Expecting strong year ahead with sustained revenue growth and enhanced productivity.
Opportunities:
Continued demand for plasma and IG replacement therapies supporting long-term growth in plasma collections market.
New product launches like VASCADE MVP XL facilitating expansion in interventional procedures such as pulsed field ablation and left atrial appendage closures.
Risks:
Plasma revenue decline of 3%, influenced by customer transitions and unforeseen temporary customer plasma center outages.
Blood Center revenue decreased by 2% due to order timing among distributors and rationalizing the franchise to optimize contribution.
More details: Haemonetics IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
